ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) registered a 0.72% increase, still its new closing price is 445.08% up from the company’s 1 year high of 23.81.It posted 0.34% gains in previous 5 sessions and is now the subject of 7 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 9 stock analysts following this company have an average price target at $20.63, with individual PT in the $14.00-$24.00 range. The shares moved at $23.82, implying that brokerage firms see shares gaining about 385.13% in twelve months time.

ARIAD Pharmaceuticals, Inc. (ARIA) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 91.48% rise year to date. A Sr. VP, Reg. Affairs & Quality at ARIAD Pharmaceuticals, Inc. (ARIA) offloaded shares in a transaction closed on Monday January 09, 2017. Bollag Daniel M sold 32,000 shares in the company at $23.78 each and collected $760,001 in proceeds. Bollag Daniel M now owns 129,404 shares in the company after this transaction. A President, R&D, CSO in the company, CLACKSON TIMOTHY P, disclosed a transaction on Monday October 24, 2016 that ended up generating $187,001 from the sale of 19,638 shares at $9.56 per share.

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) Upcoming Results on Tap

ARIAD Pharmaceuticals, Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.16 in that period. Sales during the quarter are predicted to arrive at $43.71 million.

Earnings surprise history: Last quarter, the company posted approximately $46.02 million in revenue and EPS of $-0.14. The mean forecast was for $42.92 million and $-0.19 a share, respectively. One quarter earlier, revenue for the stock was at $68.12 million, with earnings at $0.56/share.

ARIAD Pharmaceuticals, Inc. (ARIA) Brokerage Update 

ARIAD Pharmaceuticals, Inc. (ARIA) is in SunTrust’s research list so their analyst rating change is noteworthy. These shares were downgraded to Hold from Buy by SunTrust, according to news reported on Wednesday January 11, 2017.Another important research note was issued by Leerink Partners on Tuesday January 10, 2017.The firm downgraded ARIA to Mkt Perform from Outperform. Over the last six months and over the last three months, the shares of ARIAD Pharmaceuticals, Inc. (ARIA), have changed 145.31% and 171.30%, respectively.